The effects of antagonists of GHRH and the
somatostatin analog
RC-160 on the growth of OV-1063 human
epithelial ovarian cancer cells xenografted into nude mice were investigated. Treatment with 20 microg/day of the GHRH antagonist
JV-1-36 or
MZ-5-156 and 60 microg/day of the
somatostatin analog
RC-160 for 25 days decreased
tumor volume by 70.9% (P < 0.01), 58.3% (P < 0.05), and 60.6% (P < 0.01), respectively, vs. the control value. The levels of GH in serum were decreased in all of the treated groups, but only
RC-160 significantly reduced serum
insulin-like growth factor I (
IGF-I). The levels of messenger
ribonucleic acid (
mRNA) for
IGF-I and -II and for their receptors in OV-1063
tumors were investigated by multiplex RT-PCR. No expression of
mRNA for
IGF-I was detected, but treatment with JV-1-136 caused a 51.8% decrease (P < 0.05) in the level of
mRNA for
IGF-II in
tumors. Exposure of OV-1063 cells cultured in vitro to GHRH,
IGF-I, or
IGF-II significantly (P < 0.05) stimulated cell growth, but 10(-5) mol/L
JV-1-36 nearly completely inhibited (P < 0.001) OV-1063 cell proliferation. OV-1063
tumors expressed
mRNA for
GHRH receptors and showed the presence of binding sites for GHRH. Our results indicate that antagonistic analogs of GHRH and the
somatostatin analog
RC-160 inhibit the growth of
epithelial ovarian cancers. The effects of
RC-160 seem to be exerted more on the pituitary GH-hepatic
IGF-I axis, whereas GHRH antagonists appear to reduce
IGF-II production and interfere with the autocrine regulatory pathway. The antitumorigenic action of GHRH antagonists appears to be mediated by
GHRH receptors found in OV-1063
tumors.